Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

rAAVrh74.MHCK7.DYSF.DV

Gene therapy (AAV vector) · Gene replacement · developed by Sarepta Therapeutics

Phase 1 Most advanced trial (none active)
SRPT Developer
1 Registered trials

What is rAAVrh74.MHCK7.DYSF.DV?

rAAVrh74.MHCK7.DYSF.DV is a recombinant adeno-associated virus vector carrying a dysferlin (DYSF) transgene under a muscle-specific MHCK7 promoter. It is designed to deliver the dysferlin gene to muscle and is studied in dysferlinopathy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Neurology
Developer
Sarepta Therapeutics, Inc. (SRPT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02710500 Phase 1 Dysferlinopathy Completed SRPT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dysferlinopathy

More from Sarepta Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.

Follow SRPT, the company behind rAAVrh74.MHCK7.DYSF.DV

See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SRPT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.